Secukinumab in the treatment of psoriasis: patient selection and perspectives

Eric J Yang,1,2 Kristen M Beck,1 Wilson Liao1 1Department of Dermatology, University of California San Francisco, San Francisco, CA, USA; 2Chicago Medical School, Rosalind Franklin University of Medicine and Science, North Chicago, IL, USA Abstract: Secukinumab is a human monoclonal antibody targeti...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Yang EJ, Beck KM, Liao W
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2018
Materias:	secukinumab IL-17 inhibitor IL-17A biologics psoriasis patient selection Dermatology RL1-803
Acceso en línea:	https://doaj.org/article/9b7488745a654ceda2223efe2fd2ac39
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:9b7488745a654ceda2223efe2fd2ac39
record_format	dspace
spelling	oai:doaj.org-article:9b7488745a654ceda2223efe2fd2ac392021-12-02T11:21:07ZSecukinumab in the treatment of psoriasis: patient selection and perspectives2230-326Xhttps://doaj.org/article/9b7488745a654ceda2223efe2fd2ac392018-10-01T00:00:00Zhttps://www.dovepress.com/secukinumab-in-the-treatment-of-psoriasis-patient-selection-and-perspe-peer-reviewed-article-PTThttps://doaj.org/toc/2230-326XEric J Yang,1,2 Kristen M Beck,1 Wilson Liao1 1Department of Dermatology, University of California San Francisco, San Francisco, CA, USA; 2Chicago Medical School, Rosalind Franklin University of Medicine and Science, North Chicago, IL, USA Abstract: Secukinumab is a human monoclonal antibody targeting IL-17A that has been approved for three indications: moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis. In Phase III clinical trials for each of these three indications, secukinumab has proven to be both highly efficacious and well-tolerated. However, several biologic medications are currently approved for the treatment of moderate-to-severe plaque psoriasis, and many demonstrate excellent efficacy and safety. Due to this wide selection, it is often unclear how to choose biologics for specific patients. Important considerations in biologic selection include clinical efficacy, safety, cost, convenience, onset of action, and management of comorbid disease. This article aims to outline the key considerations in patient selection for the treatment of plaque psoriasis with secukinumab. Keywords: secukinumab, IL-17 inhibitor, IL-17A, biologics, psoriasis, patient selectionYang EJBeck KMLiao WDove Medical PressarticlesecukinumabIL-17 inhibitorIL-17Abiologicspsoriasispatient selectionDermatologyRL1-803ENPsoriasis: Targets and Therapy, Vol Volume 8, Pp 75-82 (2018)
institution	DOAJ
collection	DOAJ
language	EN
topic	secukinumab IL-17 inhibitor IL-17A biologics psoriasis patient selection Dermatology RL1-803
spellingShingle	secukinumab IL-17 inhibitor IL-17A biologics psoriasis patient selection Dermatology RL1-803 Yang EJ Beck KM Liao W Secukinumab in the treatment of psoriasis: patient selection and perspectives
description	Eric J Yang,1,2 Kristen M Beck,1 Wilson Liao1 1Department of Dermatology, University of California San Francisco, San Francisco, CA, USA; 2Chicago Medical School, Rosalind Franklin University of Medicine and Science, North Chicago, IL, USA Abstract: Secukinumab is a human monoclonal antibody targeting IL-17A that has been approved for three indications: moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis. In Phase III clinical trials for each of these three indications, secukinumab has proven to be both highly efficacious and well-tolerated. However, several biologic medications are currently approved for the treatment of moderate-to-severe plaque psoriasis, and many demonstrate excellent efficacy and safety. Due to this wide selection, it is often unclear how to choose biologics for specific patients. Important considerations in biologic selection include clinical efficacy, safety, cost, convenience, onset of action, and management of comorbid disease. This article aims to outline the key considerations in patient selection for the treatment of plaque psoriasis with secukinumab. Keywords: secukinumab, IL-17 inhibitor, IL-17A, biologics, psoriasis, patient selection
format	article
author	Yang EJ Beck KM Liao W
author_facet	Yang EJ Beck KM Liao W
author_sort	Yang EJ
title	Secukinumab in the treatment of psoriasis: patient selection and perspectives
title_short	Secukinumab in the treatment of psoriasis: patient selection and perspectives
title_full	Secukinumab in the treatment of psoriasis: patient selection and perspectives
title_fullStr	Secukinumab in the treatment of psoriasis: patient selection and perspectives
title_full_unstemmed	Secukinumab in the treatment of psoriasis: patient selection and perspectives
title_sort	secukinumab in the treatment of psoriasis: patient selection and perspectives
publisher	Dove Medical Press
publishDate	2018
url	https://doaj.org/article/9b7488745a654ceda2223efe2fd2ac39
work_keys_str_mv	AT yangej secukinumabinthetreatmentofpsoriasispatientselectionandperspectives AT beckkm secukinumabinthetreatmentofpsoriasispatientselectionandperspectives AT liaow secukinumabinthetreatmentofpsoriasispatientselectionandperspectives
_version_	1718396000251412480

Secukinumab in the treatment of psoriasis: patient selection and perspectives

Ejemplares similares